Search Videos and More
Video
Bladder Cancer Highlights presented by Michael Serzan, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from ASCO 2024.
Video
Kidney Cancer Highlights presented by Michael Serzan, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2024.
Video
Prostate Cancer Highlights presented by Michael Serzan, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ASCO 2024.
News
Study Highlights the Importance of Infection Prevention After CAR T-Cell Therapy
A systematic review and meta-analysis of non-relapse mortality after CAR T-cell therapy.
News
Finding New Vulnerabilities in Uterine and Ovarian Cancers
Just like humans, cells get stressed, too — especially cancer cells. For decades, Dana-Farber researchers have been characterizing a complex molecular condition in cancer cells known as DNA replication stress.
News
Antibody-Drug Conjugate Highly Effective in Preventing Recurrence in Patients with Early Stage HER2+ Breast Cancer, Trial Finds
A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute researchers has found.
Symposium
2025 American Society of Clinical Oncology (ASCO)
Review video summaries and oral abstracts from Dana-Farber physician-scientists at the ASCO 2025 Annual Meeting.
Symposium
ASCO 2025: GU Highlights
In the following videos, Faculty from Dana-Farber Cancer Institute review GU Oncology highlights from the 2025 ASCO Annual Meeting, held in Chicago, May 30 - June 3, 2025.
News
Disparities Research Symposium Focuses on Clinical Trials
Above all else, clinical research is about action – moving promising findings from the lab to patient care. The same can now be said about addressing disparities in clinical trial participation: that such disparities exist is well documented; the question going forward is how to reduce them.
Document
Treatment Guideline: Adjuvant Abemaciclib for Early-Stage, Hormone-Receptor-Positive Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of adjuvant abemaciclib in patients with early-stage, hormone-receptor-positive breast cancer.
Document
Treatment Guideline: Adjuvant Ribociclib for Early-Stage Hormone Receptor-Positive Breast Cancer - Updated in 2025
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of adjuvant ribociclib in patients with early-stage hormone receptor-positive breast cancer.
Document
Treatment Guideline: Patients With a History of Breast Cancer who Desire Pregnancy
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations for patients with a history of breast cancer who desire pregnancy.